We would like to thank Dr. Hesham Abdelbary for providing human surgical specimens for the data presented in Fig 2.

1. Tissue processing
<ol>
<li>For best results, this protocol should be performed using freshly isolated tissue deposited in DMEM media containing 10% FBS, 1% Pennicilin /Streptomycin solution, and 0.1% Amphothericin B solution immediately following surgery prior to processing. If this is not possible, tissues can be left overnight in this medium at 4 degrees prior to processing.</li>
<li>Prior to processing the sample, sterilize metal forceps and disposable blades by depositing them in a 70% ethanol solution for at least 5 minutes. Also prepare a 24-well plate with 2 ml of DMEM media containing 10% FBS, 1% Pennicilin /Streptomycin solution, and 0.1% Amphothericin B.</li> 
<li>Collect the tissue sample in a laminar flow cell culture hood using sterilized forceps and deposit the tissue in an empty 15 cm petri dish, keeping the lid on the side, sterile side up.</li> 
<li>In the cell culture hood, use a 2 mm biopsy punch to obtain different cores from a variety of regions within the tissue as in Figure 1. Deposit the cores in the lid of the 15 cm petri with the help of forceps, leaving enough space in between each core so that they can be easily cut along the horizontal axis.</li>
<li>Split each core into 4 even quarters using a sterilized razor blade as in Figure 1.</li>
<li>Using a pipet tip, put each core quarter from a given core in a different well from A1 to A4 as in figure 1, already containing 1.5 ml of DMEM containing 10% FBS, 1% Pennicilin /Streptomycin solution, and 0.1% Amphothericin B solution. Repeat for each core. This should allow representative sampling of the tumor, while minimizing bias in a given well/condition. For better representation, increase the number of cores.</li>
</ol>
2. Assessment of tissue viability
<ol>
<li>Following tissue processing, add 25&mu;l Alamar blue to well # A1 and # A2 as shown in figure 1 and incubate for 1 hour at 37 degrees in a humidified incubator with 5% CO2.</li>
<li>Following incubation with alamar blue, remove 3 times 100 &mu;l from each A1 and A2 well and transfer to 6 different wells of a 96-well plate. Read the signal using a fluorescence plate reader (530 excitation, 590 emission) and keep the data for your records.</li>
<li>After Alamar blue signal has been read, transfer all pieces of tissue using a pipet tip, from well A1 to C1 that contains DMEM, 10% FBS + PS + AmphoB. Be careful not to transfer an excessive amount of media from well A1.</li>
<li>Infect wells A3 and A4 respectively with 106 PFU of GFP-expressing and luciferase-expressing vaccinia virus diluted in 25 &mu;l of media. Well A2 can be infected with a virus that that expresses any given transgene including none at all.</li>
<li>72 hours later, add 25 &mu;l Alamar blue to wells C1 and D1 and repeat step 2.2</li>
</ol>
3. Visualization of GFP transgene expression by florescence microscopy
<ol>
<li>Remove all cell culture media covering the tissue pieces in order to take good fluorescence pictures.</li> 
<li>Using a fluorescence-capable dissection microscope, first take a phase contrast image at an appropriate resolution</li>
<li>Switch to fluorescence mode and take a picture using the appropriate filter to visualize the transgene of interest, in this case GFP.</li>
<li>Use a fluorescence filter for another wavelength as far a possible from that of the transgene of interest (such as RFP) to take a picture of background fluorescence</li>
</ol>
4. Visualization of luciferase expression using an In Vivo imaging System (IVIS)
<ol>
<li>Make sure that the IVIS is initialized before you begin.</li> 
<li>In wells A4 and B4, add 5 &mu;l of luciferin substrate 10 mg/ml, mix well and incubate for 5 minutes at room temperature.</li> 
<li>Set the IVIS exposure time to 5 seconds and take a picture of your wells. If the image is saturated, repeat with lower exposure time. If there is no signal, increase the exposure time.</li>
<li>Using the IVIS imaging software, you may remove background using the signal from well B4 and select the region of interest to quantify the luminescence signal.</li>
</ol>
5. Assessing viral titers by plaque assay
<ol>
<li>Prior to quantifying viral titers, tissues must first be homogenized to release viral particles. This can be done several months later in the infected tissue samples are stored at -80</li>
<li>Weigh the sample that needs to be homogenized using an analytical scale. In this case, we will use the sample collected from well A2.</li>
<li>Place the tissue is in a 5 ml polystyrene round-bottom falcon tube and add 1 ml of PBS. Homogenize the tissue using a tissue homogenizer. If necessary, store the homogenate at -80 for assessment of viral titers at a later time.</li>
<li>To titer vaccinia virus, first plate 1 million U2OS cells in a 6-well plate and incubate overnight in a 37 degree, 5% CO2 humidified incubator such that they have reached approximately 95 % confluency the following day.</li> 
<li>Use serum free media to do serial dilutions of virus, making sure to change tips between each dilution step. Typically we do 1 in 10 dilutions and use 100 &mu;l to transfer into 900 &mu;l. How many dilutions are made depends on the anticipated virus yield.</li>
<li>Following making the dilutions, remove the media covering the plated U20S cells then add 500 &mu;l of diluted virus stock (for each dilution) to infect the U2OS cells. Incubate the cells for 1 hour minutes at 37 degrees Celcius in a 5% CO2 humidified incubator.</li>
<li>During this time, warm up the 2 X concentrated DMEM containing 20% FBS, and the 3% CMC solution in a 37 degree water bath.</li> 
<li>After the 1 hour incubation, remove the media covering infected U2OS cells. Mix 1:1 volumes of 3% CMC : 2X DMEM, 20% FBS together and use 2 ml of this mixture to cover each well of the infected U2OS cells.</li> 
<li>Put cells back in a 37 degree 5% CO2 humidified incubator for another 48 hours.</li>
<li>After 48 hours, add 2 ml of methanol-acetic acid fixative on top of the CMC overlay in each well and incubate at room temperature for 10 minutes in a cell culture hood.</li> 
<li>Discard the fixed overlay and wash remainder off of the wells using tap water.</li> 
<li>Stain the fixed U2OS cells with 2ml of a coomassie blue solution per well and incubate for 30 minutes at room temperature at low speed on a plate shaker.</li> 
<li>Remove the coomassie stain from the wells and wash the plates using tap water. Allow to dry with lid off for about an hour.</li>
<li>The Resulting viral plaques can be easily visualized in figure 2C. Plates can be stored indefinitely at this stage.</li> 
<li>Count plaques at the dilution step where between 10 and 100 plaques are visible.</li> 
<li>Multiply the number of plaques counted by the dilution used and multiply the resulting number by 2 to give a titer in PFU/ml. For example, if 25 plaques are counted in the well where a million-fold dilution was used, the titer of the initial undiluted sample is 25 multiplied by 1 million multiplied by 2 or 50 million PFU/ml. Further divide this number by the weight initially measure for the sample to report titers in PFU/g</li>
</ol>
6. Representative Results: 
In order to accurately determine whether a surgically obtained normal/tumor tissue sample is or is not infectable with virus, one must first ensure that the tissue sample is at least viable. Fig 1A shows that viability can be assessed using a metabolic dye (Alamar blue) and that both normal and tumor tissue can remain metabolically active over a period of at least 72h. This suggests that tissues cultured ex vivo can support viral replication. A significant advantage of oncolytic viruses is that they can be engineered to express therapeutic or imaging transgenes. Fig 2D-E shows that GFP or Luciferase can be detected from tissues infected ex vivo, further supporting that these tissues are viable and also infectable. Although increased transgene expression is generally associated with viral replication, it does not necessarily equate to a productive viral life cycle that leads to self-amplification and spread, which is thought to be important for therapeutic activity. For this reason, it is necessary to determine whether more virus is produced than what was used to initially infect the tissue. Fig 2B shows that upon viral quantification by plaque assay, more virus is obtained after 72 hours infection then tissue collected immediately after infection. Overall, these data show that surgically excised tumor tissue can remain viable in cell culture for a period of at least 72 hours, during which time viral replication can be supported.
<img src="/files/ftp_upload/2854/2854fig1.jpg" alt="Figure 1"/> 
Figure 1. Overview of the tissue sampling / sectioning protocol. Tissue sample is processed by removing several 2 mm cores which are subsequently divided into four quarters which are randomly distributed into wells A1-A4. The color codes indicate the reagents used in each well. The grey-shaded squares within the wells represent each quarter from the 6 individual cores depicted. The tissue in well A1 is transferred to a new well (C1) with media after the initial alamar blue reading. A second reading is done at the end of the 72 hour incubation with viruses. Wells A4 and B4 are supplemented with Luciferin after the 72 hour incubation post-infection
<img src="/files/ftp_upload/2854/2854fig2.jpg" alt="Figure 2"/> 
Figure 2. Viability and infectability of patient tissue samples. A) Tissue viability as measured by alamar blue signal at 2 hours and 72 hours post collection. Y-axis represents the blank corrected alamar blue signal. B) Titer of vaccinia virus collected per gram of tissue samples 2 and 72 hours post-infection. C) Example of vaccinia virus plaques on U2OS cells following coomassie staining. D) Luminescence signal obtained from patient VV-luciferase-infected tissue imaged using IVIS. E) Fluorescence microscopy pictures of patient tissue sample infected with VV-GFP.

<ol>
	<li>Parato, K. A., Senger, D., Forsyth, P. A., Bell, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Recent+progress+in+the+battle+between+oncolytic+viruses+and+cancer.">Recent progress in the battle between oncolytic viruses and cancer.</a> Nat Rev Cancer. 5, 965-976 (2005).</li><li>Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., Newbold, K. L., Goldsweig, H., Coffin, R., Nutting, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phase+I/II+study+of+oncolytic+HSV+GM-CSF+in+combination+with+radiotherapy+and+cisplatin+in+untreated+stage+III/IV+squamous+cell+cancer+of+the+head+and+neck.">Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.</a> Clin Cancer Res. 16, 4005-4015 (2010).</li><li>Lal, R., Harris, D., Postel-Vinay, S., de Bono, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reovirus:+Rationale+and+clinical+trial+update.">Reovirus: Rationale and clinical trial update.</a> Curr Opin Mol Ther. 11, 532-539 (2009).</li><li>Park, B. H., Hwang, T., Liu, T. C., Sze, D. Y., Kim, J. S., Kwon, H. C., Oh, S. Y., Han, S. Y., Yoon, J. H., Hong, S. H., Moon, A., Speth, K., Park, C., Ahn, Y. J., Daneshmand, M., Rhee, B. G., Pinedo, H. M., Bell, J. C., Kirn, D. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+a+targeted+oncolytic+poxvirus,+JX-594,+in+patients+with+refractory+primary+or+metastatic+liver+cancer:+a+phase+I+trial.">Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.</a> Lancet Oncol. 9, 533-542 (2008).</li><li>Breitbach, C. J., Reid, T., Burke, J., Bell, J. C., Kirn, D. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Navigating+the+clinical+development+landscape+for+oncolytic+viruses+and+other+cancer+therapeutics:+no+shortcuts+on+the+road+to+approval.+Cytokine+Growth+Factor+Rev.">Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev.</a> 21, 85-89 (2010).</li><li>Boeuf, F. L. e. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synergistic+interaction+between+oncolytic+viruses+augments+tumor+killing.">Synergistic interaction between oncolytic viruses augments tumor killing.</a> Mol Ther. 18, 888-895 (2010).</li><li>Silva, N. D. e., Atkins, H., Kirn, D. H., Bell, J. C., Breitbach, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Double+trouble+for+tumours:+exploiting+the+tumour+microenvironment+to+enhance+anticancer+effect+of+oncolytic+viruses.">Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.</a> Cytokine Growth Factor Rev. 21, 135-141 (2010).</li><li>Diallo, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+high-throughput+pharmacoviral+approach+identifies+novel+oncolytic+virus+sensitizers.">A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.</a> Mol Ther. 18, 1123-1129 (2010).</li><li>Cooke, S. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intra-tumour+genetic+heterogeneity+and+poor+chemoradiotherapy+response+in+cervical+cancer.">Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.</a> Br J Cancer. , (2010).</li><li>Pennington, K., Chu, Q. D., Curiel, D. T., Li, B. D. L., Mathis, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Utility+of+a+Tissue+Slice+Model+System+to+Determine+Breast+Cancer+Infectivity+by+Oncolytic+Adenoviruses.">The Utility of a Tissue Slice Model System to Determine Breast Cancer Infectivity by Oncolytic Adenoviruses.</a> J Surg Res. , 1-6 (2010).</li><li>Hochberg, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tropism+of+herpes+simplex+virus+type+1+to+non-melanoma+skin+cancers.">Tropism of herpes simplex virus type 1 to non-melanoma skin cancers.</a> Br J Dermatol. , (2010).</li><li>Kuip, H. v. a. n. d. e. r. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Short+term+culture+of+breast+cancer+tissues+to+study+the+activity+of+the+anticancer+drug+taxol+in+an+intact+tumor+environment.">Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.</a> BMC Cancer. 6, 86-86 (2006).</li></ol>

No conflicts of interest declared.

One of the critical steps in this protocol is obtaining fresh tissue sample. If the sample is put into cell culture following a long wait at the operating room in an inappropriate media (eg. PBS), this may compromise tissue viability and prevent infectability. Of note, normal tissue is inherently more prone to these effects than tumor tissues. Another critical point is how many cores are used to sample the tissue and the consistency of their size. Inconsistencies in size will lead to variability across patient samples since factors such as tissue hypoxia and infectectable surface will fluctuate depending on the size of the cores and core quarters. While this can be partially resolved by using tissue slicers, one advantage of the method presented here is that it is relatively easy, less prone to contamination, and widely applicable to a variety of tissue types, including soft or viscous tissues which are not easily amenable to tissue slicing. Notably, the number of cores can be increased in order to get better tissue representation. Also, the cores can be cut into more pieces (eg. 5-8) to accommodate other potential assays to be done in parallel such as DNA, RNA, or protein extraction. However, the number of pieces in which the cores can be cut to reproducible sizes will depend on the actual size of the cores, which can be modified by using different sized corers. Optionally, one way to help obtain reproducibly sized tissue pieces is to even out the length of the cores using a ruler prior to further subdividing them into smaller pieces. The protocol can naturally be modified to accommodate other viruses and we have found that tissues can be viable and support replication for up to 6 days. The protocol can further be extended to measurements of other virally-expressed transgenes including cytrokines. Following infection, tissues can also be embedded in paraffin for further sectioning and staining by immunohistochemical methods, which allows for further refinement of the tissue histology and how it relates to viral infection10-12.

<table border="1">
	<tbody>
 	<tr>
 	<th>Name of the reagent</th>
 <th>Company</th>
 <th>Catalogue number</th>
 <th>Comments (optional)</th>
 </tr>
 <tr>
 	<td>High glucose DMEM</td>
 <td>Hyclone</td>
 <td>SH30243.01</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>Fetal Bovine Serum</td>
 <td>NorthBio Inc.</td>
 <td>NBSF-701</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>Amphothericin B solution</td>
 <td>Sigma Aldrich</td>
 <td>A2942</td>
 <td>Use at 0.1%</td>
 </tr>
 <tr>
 	<td>Pennicilin-Streptomycin</td>
 <td>Sigma Aldrich</td>
 <td>P4333</td>
 <td>Use at 1%</td>
 </tr>
 <tr>
 	<td>Alamar Blue</td>
 <td>Invitrogen</td>
 <td>DAL1025</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>D-Luciferin potassium salt </td>
 <td>Molecular Imaging Products</td>
 <td>D-Luciferin potassium salt 1g</td>
 <td>Resuspend in PBS at 10 mg/ml and filter on 0.22 &mu;m filter</td>
 </tr>
 <tr>
 	<td>MEM powder</td>
 <td>Gibco</td>
 <td>#41500018</td>
 <td>Make in half the suggested volume to make 2X MEM and filter on 0.22 &mu;m filter prior to use</td>
 </tr>
 <tr>
 	<td>Carboxymethyl cellulose (CMC)</td>
 <td>Sigma Aldrich</td>
 <td>C9481</td>
 <td>Make a 3% solution in deionized water and autoclave. Note that powder can take some time to resuspend</td>
 </tr>
 <tr>
 	<td>Coomassie Brilliant Blue R</td>
 <td>Sigma Aldrich</td>
 <td>B7920</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>2 mm Biopsy punch</td>
 <td>Miltex</td>
 <td>MX-33-31</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>Double Edge Prep Blades</td>
 <td>Personna Medical Care</td>
 <td>74-0002</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>Fluorescence disection Microscope</td>
 <td>Leica</td>
 <td>model M205 FA</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>In vivo imaging system (IVIS) </td>
 <td>Caliper Life Sciences</td>
 <td>IVIS&reg; 200 series</td>
 <td>&nbsp;</td>
 </tr>
 <tr>
 	<td>Tissue Tearor</td>
 <td>Biospec products</td>
 <td>model 985370-395</td>
 <td>&nbsp;</td>
 </tr> 
 </tbody>
</table>

ex vivo infection of live tissue with oncolytic viruses

Oncolytic Viruses (OVs) are novel therapeutics that selectively replicate in and kill tumor cells1. Several clinical trials evaluating the effectiveness of a variety of oncolytic platforms including HSV, Reovirus, and Vaccinia OVs as treatment for cancer are currently underway2-5. One key characteristic of oncolytic viruses is that they can be genetically modified to express reporter transgenes which makes it possible to visualize the infection of tissues by microscopy or bio-luminescence imaging6,7. This offers a unique advantage since it is possible to infect tissues from patients ex vivo prior to therapy in order to ascertain the likelihood of successful oncolytic virotherapy8. To this end, it is critical to appropriately sample tissue to compensate for tissue heterogeneity and assess tissue viability, particularly prior to infection9. It is also important to follow viral replication using reporter transgenes if expressed by the oncolytic platform as well as by direct titration of tissues following homogenization in order to discriminate between abortive and productive infection. The object of this protocol is to address these issues and herein describes 1. The sampling and preparation of tumor tissue for cell culture 2. The assessment of tissue viability using the metabolic dye alamar blue 3. Ex vivo infection of cultured tissues with vaccinia virus expressing either GFP or firefly luciferase 4. Detection of transgene expression by fluorescence microscopy or using an In Vivo Imaging System (IVIS) 5. Quantification of virus by plaque assay. This comprehensive method presents several advantages including ease of tissue processing, compensation for tissue heterogeneity, control of tissue viability, and discrimination between abortive infection and bone fide viral replication.

Watch this Scientific Journal Video about Ex Vivo Infection of Live Tissue with Oncolytic Viruses at JoVE.com

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Oncolytic viruses are promising for cancer therapeutics. The ability to ascertain the infectability of live tissue specimens obtained from patients prior to treatment is a unique advantage of this therapeutic approach. This protocol describes how to process tissues for ex vivo infection with oncolytic virus and subsequent viral quantification.

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Oncolytic Viruses (OVs) are novel therapeutics that selectively replicate in and kill tumor cells1. Several clinical trials evaluating the effectiveness ...

ex-vivo-infection-of-live-tissue-with-oncolytic-viruses

Research

JoVE Journal

Medicine

12.6K Views.  Ottawa Hospital Research Institute (OHRI). Oncolytic viruses are promising for cancer therapeutics. The ability to ascertain the infectability of live tissue specimens obtained from patients prior to treatment is a unique advantage of this therapeutic approach. This protocol describes how to process tissues for ex vivo infection with oncolytic virus and subsequent viral quantification.

Video: Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Culture of Patient Tissue &amp; Examination of Gene Delivery

This video describes the use of patient tissue as an ex vivo model for the study of gene delivery. Fresh patient tissue obtained at the time of surgery is sliced and maintained in culture. The ex vivo model system allows for the physical delivery of genes into intact patient tissue and gene expression is analysed by bioluminescence imaging using the IVIS detection system. The bioluminescent detection system demonstrates rapid and accurate quantification of gene expression within individual slices without the need for tissue sacrifice. This slice tissue culture system may be used in a variety of tissue types including normal and malignant tissue and allows us to study the effects of the heterogeneous nature of intact tissue and the high degree of variability between individual patients. This model system could be used in certain situations as an alternative to animal models and as a complementary preclinical mode prior to entering clinical trial.

Ex Vivo Culture of Patient Tissue & Examination of Gene Delivery

This article describes the culture of patient tissue slices for gene delivery studies and subsequent analysis of gene expression using IVIS bioluminescence imaging.

This video describes the use of patient tissue as an ex vivo model for the study of gene delivery.  Fresh patient tissue obtained at the time of surgery ...

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Oncolytic viruses are a novel anticancer therapy with the ability to target tumor cells, while leaving healthy cells intact. For this strategy to be successful, recent studies have shown that involvement of the host immune system is essential. Therefore, oncolytic virotherapy should be evaluated within the context of an immunocompetent model. Furthermore, the study of antitumor therapies in tolerized animal models may better recapitulate results seen in clinical trials. Cotton rats, commonly used to study respiratory viruses, are an attractive model to study oncolytic virotherapy as syngeneic models of mammary carcinoma and osteosarcoma are well established. However, there is a lack of published information on the proper handling procedure for these highly excitable rodents. The handling and capture approach outlined minimizes animal stress to facilitate experimentation. This technique hinges upon the ability of the researcher to keep calm during handling and perform procedures in a timely fashion. Finally, we describe how to prepare cotton rat mammary tumor cells for consistent subcutaneous tumor formation, and how to perform intratumoral and intraperitoneal injections. These methods can be applied to a wide range of studies furthering the development of the cotton rat as a relevant pre-clinical model to study antitumor therapy.

Cotton rats are extremely excitable and have a strong flight-or-fight response. A handling method optimized to reduce the stress of the animals is described which will make cotton rats more accessible as a preclinical model.

Oncolytic viruses are a novel anticancer therapy with the ability to target tumor cells, while leaving healthy cells intact.  For this strategy to be ...

Ex vivo Live Imaging of Lung Metastasis and Their Microenvironment

Metastasis is a major cause for cancer-related morbidity and mortality. Metastasis is a multistep process and due to its complexity, the exact cellular and molecular processes that govern metastatic dissemination and growth are still elusive. Live imaging allows visualization of the dynamic and spatial interactions of cells and their microenvironment. Solid tumors commonly metastasize to the lungs. However, the anatomical location of the lungs poses a challenge to intravital imaging. This protocol provides a relatively simple and quick method for ex vivo live imaging of the dynamic interactions between tumor cells and their surrounding stroma within lung metastasis. Using this method, the motility of cancer cells as well as interactions between cancer cells and stromal cells in their microenvironment can be visualized in real time for several hours. By using transgenic fluorescent reporter mice, a fluorescent cell line, injectable fluorescently labeled molecules and/or antibodies, multiple components of the lung microenvironment can be visualized, such as blood vessels and immune cells. To image the different cell types, a spinning disk confocal microscope that allows long-term continuous imaging with rapid, four-color image acquisition has been used. Time-lapse movies compiled from images collected over multiple positions and focal planes show interactions between live metastatic and immune cells for at least 4 hr. This technique can be further used to test chemotherapy or targeted therapy. Moreover, this method could be adapted for the study of other lung-related pathologies that may affect the lung microenvironment.

Ex vivo Live Imaging of Lung Metastasis and Their Microenvironment

We describe a relatively simple method for ex vivo live imaging of the tumor cell-stroma interactions within lung metastasis, utilizing fluorescent reporters in mice. Using spinning-disk confocal microscopy, this technique enables visualization of live cells for at least 4 hr and could be adapted to study other inflammatory lung conditions.

Metastasis is a major cause for cancer-related morbidity and mortality. Metastasis is a multistep process and due to its complexity, the exact cellular ...

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Hepatocellular carcinoma (HCC) is a disease with limited treatment options and poor prognosis. In recent years, oncolytic virotherapies have proven themselves to be potentially powerful tools to fight malignancy. Due to the unique dual blood supply in the liver, it is possible to apply therapies locally to orthotopic liver tumors, which are predominantly fed by arterial blood flow. We have previously demonstrated that hepatic arterial delivery of oncolytic viruses results in safe and efficient transduction efficiency of multifocal HCC lesions, resulting in significant prolongation of survival in immune competent rats. This procedure closely mimics the application of transarterial embolization in patients, which is the standard palliative care provided to many HCC patients. The ability to administer tumor therapies through the hepatic artery in rats allows for a highly sophisticated preclinical model for evaluating novel viral vectors under development. Here we describe the detailed protocol for microdissection of the hepatic artery for infusion of oncolytic virus vectors to treat orthotopic HCC.

Oncolytic virotherapies are under development as novel therapeutics for the treatment of hepatocellular carcinoma (HCC). Here we describe a method for locoregional therapy of HCC via hepatic arterial administration of oncolytic virus.

Hepatocellular carcinoma (HCC) is a disease with limited treatment options and poor prognosis.  In recent years, oncolytic virotherapies have proven ...

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Human small intestinal enteroids are derived from the crypts and when grown in a stem cell niche contain all of the epithelial cell types. The ability to establish human enteroid ex vivo culture systems are important to model intestinal pathophysiology and to study the particular cellular responses involved. In recent years, enteroids from mice and humans are being cultured, passaged, and banked away for future use in several laboratories across the world. This enteroid platform can be used to test the effects of various treatments and drugs and what effects are exerted on different cell types in the intestine. Here, a protocol for establishing primary stem cell-derived small intestinal enteroids derived from neonatal mice and premature human intestine is provided. Moreover, this enteroid culture system was utilized to test the effects of species-specific breast milk. Mouse breast milk can be obtained efficiently using a modified human breast pump and expressed mouse milk can then be used for further research experiments. We now demonstrate the effects of expressed mouse, human, and donor breast milk on the growth and proliferation of enteroids derived from neonatal mice or premature human small intestine.

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

This protocol describes how to establish an enteroid culture system from neonatal mouse or premature human intestine as well as an efficient method to collect milk from mice.

Human small intestinal enteroids are derived from the crypts and when grown in a stem cell niche contain all of the epithelial cell types. The ability to ...

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

The assessment of modern sub-unit vaccines reveals that the generation of neutralizing antibodies is important but not sufficient for adjuvant selection. Therefore, adjuvants with both humoral and cellular immuno-stimulatory capabilities that are able to promote cytotoxic T lymphocytes (CTL) responses are urgently needed. Thus, faithful monitoring of adjuvant candidates that induce cross-priming and subsequently enhance CTL generation represents a crucial step in vaccine development. In here we present an application for a method that uses SIINFEKL-specific (OT-I) T cells to monitor the cross-presentation of the model antigen ovalbumin (OVA) in vivo in the presence of different adjuvant candidates. This method represents a rapid test to select adjuvants with the best cross-priming capabilities. The proliferation of CD8+ T cells is the most valuable indication of cross-priming and it is also regarded as a correlate of adjuvant-induced cross-presentation. This feature can be evaluated in different immune organs like lymph nodes and spleen. The extent of the CTL generation can also be monitored, thereby giving insights on the nature of a local (draining lymph node mainly) or a systemic response (distant lymph nodes and/or spleen). This technique further allows multiple modifications for testing drugs that can inhibit specific cross-presentation pathways and also offers the possibility to be used in different strains of conventional and genetically modified mice. In summary, the application that we present here will be useful for vaccine laboratories in industry or academia that develop or modify chemical adjuvants for vaccine research and development.

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

We present here an application for a standard immunological technique (CFSE stained OT-I proliferation) intended to rapidly monitor adjuvant-mediated cytotoxic T lymphocyte (CTL) generation in vivo. This fast estimation of CTL capacities is useful for the development of prophylactic vaccines against intracellular pathogens as well as therapeutic cancer vaccines.

The assessment of modern sub-unit vaccines reveals that the generation of neutralizing antibodies is important but not sufficient for adjuvant selection. ...

A Small Animal Model of Ex Vivo Normothermic Liver Perfusion

There is a significant shortage of liver allografts available for transplantation, and in response the donor criteria have been expanded. As a result, normothermic ex vivo liver perfusion (NEVLP) has been introduced as a method to evaluate and modify organ function. NEVLP has many advantages in comparison to hypothermic and subnormothermic perfusion including reduced preservation injury, restoration of normal organ function under physiologic conditions, assessment of organ performance, and as a platform for organ repair, remodeling, and modification. Both murine and porcine NEVLP models have been described. We demonstrate a rat model of NEVLP and use this model to show one of its important applications &#8212; the use of a therapeutic molecule added to liver perfusate. Catalase is an endogenous reactive oxygen species (ROS) scavenger and has been demonstrated to decrease ischemia-reperfusion in the eye, brain, and lung. Pegylation has been shown to target catalase to the endothelium. Here, we added pegylated-catalase (PEG-CAT) to the base perfusate and demonstrated its ability to mitigate liver preservation injury. An advantage of our rodent NEVLP model is that it is inexpensive in comparison to larger animal models. A limitation of this study is that it does not currently include post-perfusion liver transplantation. Therefore, prediction of the function of the organ post-transplantation cannot be made with certainty. However, the rat liver transplant model is well established and certainly could be used in conjunction with this model. In conclusion, we have demonstrated an inexpensive, simple, easily replicable NEVLP model using rats. Applications of this model can include testing novel perfusates and perfusate additives, testing software designed for organ evaluation, and experiments designed to repair organs.

A Small Animal Model of Ex Vivo Normothermic Liver Perfusion

There is a significant liver donor shortage, and criteria for liver donors have been expanded. Normothermic ex vivo liver perfusion (NEVLP) has been developed to evaluate and modify organ function. This study demonstrates a rat model of NEVLP and tests the ability of pegylated-catalase, to mitigate liver preservation injury.

There is a significant shortage of liver allografts available for transplantation, and in response the donor criteria have been expanded. As a result, ...

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

The cornea has been used extensively as a model system to study wound healing. The ability to generate and utilize primary mammalian cells in two dimensional (2D) and three dimensional (3D) culture has generated a wealth of information not only about corneal biology but also about wound healing, myofibroblast biology, and scarring in general. The goal of the protocol is an assay system for quantifying myofibroblast development, which characterizes scarring. We demonstrate a corneal organ culture ex vivo model using pig eyes. In this anterior keratectomy wound, corneas still in the globe are wounded with a circular blade called a trephine. A plug of approximately 1/3 of the anterior cornea is removed including the epithelium, the basement membrane, and the anterior part of the stroma. After wounding, corneas are cut from the globe, mounted on a collagen/agar base, and cultured for two weeks in supplemented-serum free medium with stabilized vitamin C to augment cell proliferation and extracellular matrix secretion by resident fibroblasts. Activation of myofibroblasts in the anterior stroma is evident in the healed cornea. This model can be used to assay wound closure, the development of myofibroblasts and fibrotic markers, and for toxicology studies. In addition, the effects of small molecule inhibitors as well as lipid-mediated siRNA transfection for gene knockdown can be tested in this system.

A protocol for an ex vivo corneal organ culture model useful for wound healing studies is described. This model system can be used to assess the effects of agents to promote regenerative healing or drug toxicity in an organized 3D multicellular environment.

The cornea has been used extensively as a model system to study wound healing. The ability to generate and utilize primary mammalian cells in two ...

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and one of the leading causes of blindness in working-age adults. No current animal models of diabetes and oxygen-induced retinopathy develop the full-range progressive changes manifested in human proliferative diabetic retinopathy (PDR). Therefore, understanding of the disease pathogenesis and pathophysiology has relied largely on the use of histological sections and vitreous samples in approaches that only provide steady-state information on the involved pathogenic factors. Increasing evidence indicates that dynamic cell-cell and cell-extracellular matrix (ECM) interactions in the context of three-dimensional (3D) microenvironments are essential for the mechanistic and functional studies towards the development of new treatment strategies. Therefore, we hypothesized that the pathological fibrovascular tissue surgically excised from eyes with PDR could be utilized to reliably unravel the cellular and molecular mechanisms of this devastating disease and to test the potential for novel clinical interventions. Towards this end, we developed a novel method for 3D ex vivo culture of surgically-excised patient-derived fibrovascular tissue (FT), which will serve as a relevant model of human PDR pathophysiology. The FTs are dissected into explants and embedded in fibrin matrix for ex vivo culture and 3D characterization. Whole-mount immunofluorescence of the native FTs and end-point cultures allows thorough investigation of tissue composition and multicellular processes, highlighting the importance of 3D tissue-level characterization for uncovering relevant features of PDR pathophysiology. This model will allow the simultaneous assessment of molecular mechanisms, cellular/tissue processes and treatment responses in the complex context of dynamic biochemical and physical interactions within the PDR tissue architecture and microenvironment. Since this model recapitulates PDR pathophysiology, it will also be amenable for testing or developing new treatments.

Here, we present a protocol to study the pathophysiology of proliferative diabetic retinopathy by using patient-derived, surgically-excised, fibrovascular tissues for three-dimensional native tissue characterization and ex vivo culture. This ex vivo culture model is also amenable for testing or developing new treatments.

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and one of the leading causes of blindness in working-age adults. No ...

Immunofluorescence Labelling of Human and Murine Neutrophil Extracellular Traps in Paraffin-Embedded Tissue

Neutrophil granulocytes, also called polymorphonuclear leukocytes (PMN) due to their lobulated nucleus, are the most abundant type of leukocytes. They mature in the bone marrow and are released into the peripheral blood, where they circulate for about 6&#8722;8 h; however, in tissue, they can survive for days. By diapedesis through the endothelium, they leave the blood stream, enter tissues, and migrate towards the site of an infection following chemotactic gradients.&#160;Neutrophils can combat invading microorganisms by phagocytosis,&#160;degranulation, and generation of neutrophil extracellular traps (NETs). This protocol will help to detect NETs in paraffin-embedded tissue. NETs are the result of a process called NETosis, which leads to the release of nuclear, granular, and cytoplasmic components either from living (vital NETosis) or dying (suicidal NETosis) neutrophils. In vitro, NETs form cloud-like structures, which occupy a space several times larger than that of the cells from which they descended. The backbone of NETs is chromatin, to which a selection of proteins and peptides originating from granules and cytoplasm are bound. Thereby, a high local concentration of toxic compounds is maintained so that NETs can capture and inactivate a variety of pathogens including bacteria, fungi, viruses, and parasites, while diffusion of the highly active NET components leading to damage in neighboring tissue is limited. Nevertheless, in recent years it has become apparent that NETs, if generated in abundance or cleared insufficiently, do have pathological potential ranging from autoimmune diseases to cancer. Thus, detection of NETs in tissue samples may have diagnostic significance, and the detection of NETs in diseased tissue can influence the treatment of patients. Since paraffin-embedded tissue samples are the standard specimen used for pathological analysis, it was sought to establish a protocol for fluorescent staining of NET components in paraffin-embedded tissue using commercially available antibodies.

Neutrophil extracellular traps (NETs) are three-dimensional structures generated by stimulated neutrophil granulocytes. It has become clear in recent years that NETs are involved in a wide variety of diseases. Detection of NETs in tissue may have diagnostic relevance, so standardized protocols for labelling NET components are required.

Neutrophil granulocytes, also called polymorphonuclear leukocytes (PMN) due to their lobulated nucleus, are the most abundant type of leukocytes. They ...

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Podsumowanie

Przeglądaj więcej filmów

Rozdziały w tym wideo

Ex Vivo Culture of Patient Tissue & Examination of Gene Delivery

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Ex vivo Live Imaging of Lung Metastasis and Their Microenvironment

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

A Small Animal Model of Ex Vivo Normothermic Liver Perfusion

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Immunofluorescence Labelling of Human and Murine Neutrophil Extracellular Traps in Paraffin-Embedded Tissue